Id: acc1907
Group: 2sens
Protein: Hsp27
Gene Symbol: HSPB1
Protein Id: P04792
Protein Name: HSPB1_HUMAN
PTM: phosphorylation
Site: Ser78
Site Sequence: AAPAYSRALSRQLSSGVSEIR
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: monocytic leukemia
Disease Cellline: THP-1
Disease Info:
Drug: apigenin
Drug Info: "Apigenin is a naturally occurring flavonoid compound with demonstrated potential as an antifungal agent in the preparation of drugs against human fungal infections, and it is also being researched in drug delivery systems such as solid lipid nanoparticles (APG-SLNP) to enhance stability and bioavailability. "
Effect: inhibit
Effect Info: "Knockout of p38 or silencing of PKC affects the phosphorylation of Hsp27 at specific sites, ultimately enhancing the sensitivity of leukemia cells to apigenin-induced apoptosis."
Note:
Score: 5.0
Pubmed(PMID): 21364669
Sentence Index:
Sentence:

Sequence & Structure:

MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Unknown status squamous cell lung carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed non-small cell lung carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed prostate cancer ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Terminated prostate cancer ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 1 Completed neoplasm ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 1 Unknown status urinary bladder cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
HSPB1-Ser78
Cancer Intensity
BRCA 0.707
COAD
HGSC
ccRCC -0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 78 N Dilated cardiomyopathy Phosphorylation 34477462
S 78 P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 22012255
S 78 U Breast cancer/tumor/carcinoma Phosphorylation 17697330
S 78 U Head and neck squamous cell carcinoma Phosphorylation 34498800

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: